Pfizer (NYSE:PFE) and its partner BioNTech (NSDQ:BNTX) continue to dominate the COVID-19 vaccine market.
In 2021, Pfizer anticipates that the Comirnaty (BNT162b2) vaccine will generate $36 billion in sales.
For the sake of comparison, the company’s overall 2020 revenue was $41.9 billion.
The vaccine was the single biggest driver of revenue for the company in the third quarter, which totaled $24.1 billion overall. Compared to the same quarter last year, revenues increased 130%. Excluding Comirnaty sales, revenues grew 7% year over year.
Earlier this year, Pfizer projected that sales of the vaccine would be in the ballpark of $33.5 billion.
Pfizer-BioNTech COVID-19 vaccine. [Image courtesy of Wikimedia Commons]
Pfizer CEO Dr. Albert Bourla stressed that the global nature of its COVID-19 vaccine sales growth. “For example, more than 75% of the revenues we have recorded up through third-quarter 2021 for Comirnaty have come from supplying countries outside the U.S., and we remain on track to achieve our goal of delivering at least two billion doses to low- and middle-income countries by the end of 2022,” Bourla said in a statement.
Demand for the vaccine is could fall in 2022. Pfizer anticipates that the BNT162b2 vaccine will generate $29 billion in sales next year.
That said, health data analytics firm Airfinity was more upbeat, predicting that the Pfizer-BioNTech vaccine would rake in $54.5 billion, according to a summary by the Financial Times.
In related news, CDC advisors voted today to recommend the shot for use in children aged 5 to 11.
Pfizer is conducting clinical research testing the shot in children between the ages of 2 and 4.